Sirolimus

Generic Name
Sirolimus
Brand Names
Fyarro, Hyftor, Rapamune
Drug Type
Small Molecule
Chemical Formula
C51H79NO13
CAS Number
53123-88-9
Unique Ingredient Identifier
W36ZG6FT64
Background

Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...

Indication

Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...

Associated Conditions
Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
Associated Therapies
-
Clinical Trials
Related News

Rapalog Pharmacology (RAP PAC) Study

Phase 1
Recruiting
Conditions
Aging
Interventions
Drug: Sirolimus
Drug: Everolimus
First Posted Date
2023-07-18
Last Posted Date
2024-05-31
Lead Sponsor
University of Wisconsin, Madison
Target Recruit Count
72
Registration Number
NCT05949658
Locations
🇺🇸

University of Wisconsin, Madison, Wisconsin, United States

Sirolimus in the Treatment of Refractory/Relapsed wAIHA

Phase 2
Recruiting
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
Drug: Sirolimus
First Posted Date
2023-06-29
Last Posted Date
2023-08-21
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
22
Registration Number
NCT05925023
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

First Posted Date
2023-06-09
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
16
Registration Number
NCT05896839
Locations
🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

Keck Medicine of USC Koreatown, Los Angeles, California, United States

🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

and more 21 locations

Effect of Rapamycin in Ovarian Aging

Phase 2
Recruiting
Conditions
Perimenopausal
Interventions
Other: Placebo
Drug: Rapamycin
First Posted Date
2023-05-01
Last Posted Date
2024-07-15
Lead Sponsor
Columbia University
Target Recruit Count
50
Registration Number
NCT05836025
Locations
🇺🇸

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States

Study of Sirolimus in IgG4-related Disease

Not Applicable
Not yet recruiting
Conditions
IgG4-related Disease
Interventions
Drug: Sirolimus
First Posted Date
2023-02-28
Last Posted Date
2023-02-28
Lead Sponsor
Peking University International Hospital
Target Recruit Count
20
Registration Number
NCT05746689

Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome

First Posted Date
2022-11-04
Last Posted Date
2024-07-09
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
30
Registration Number
NCT05605665
Locations
🇨🇳

Peking university people's hospital, Beijing, Beijing, China

Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)

Phase 3
Recruiting
Conditions
Juvenile Nasopharyngeal Angiofibroma
Interventions
Drug: Sirolimus
First Posted Date
2022-09-22
Last Posted Date
2022-09-22
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
117
Registration Number
NCT05549167
Locations
🇷🇺

Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation

Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.

First Posted Date
2022-09-08
Last Posted Date
2022-09-08
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
140
Registration Number
NCT05532072
Locations
🇨🇳

First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

First Posted Date
2022-07-18
Last Posted Date
2024-10-24
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
50
Registration Number
NCT05463133
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Sirolimus in Cutaneous Sarcoidosis

Phase 2
Not yet recruiting
Conditions
Cutaneous Sarcoidosis
Sarcoidosis
Interventions
Drug: Sirolimus
First Posted Date
2022-07-14
Last Posted Date
2022-07-14
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
10
Registration Number
NCT05458492
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy